Recently posted on the UroToday web site are summaries of four “state-of-the-art” lectures on prostate cancer and its management presented a couple of weeks ago at the annual meeting of the European Association of Urology is London.
Patients and advocates can access these summaries for themselves (for free) at the links given below — but you do have to register with the UroToday web site:
- Dr. Patrick Walsh, of Johns Hopkins in Baltimore, MD, discussed “Hereditary prostate cancer”, with a focus on the importance of identifying mutations that can lead to appropriate testing of individuals at high hereditary risk for prostate cancer and allow for the development of targeted therapies.
- Dr. Philip Cornford, of the Royal Liverpool and Broadgreen Hospitals NHS Trust in Liverpool, England, lectured on “EAU Guidelines on mCRPC – An Update”, addressing the increasing complexity of when and how to do what and for which patients in the management of metastatic, castration-resistant prostate cancer (mCRPC). For additional background on this topic, see pages 84-92 of the European guidelines on prostate cancer issued in 2016.
- Dr. Silvan Boxler, of the University Hospital, in Bern, Switzerland addressed “What do urologists need to know about mpMRI targeted biopsy?”, and
- Dr. Philippe Puech, of the Université du Droit et de la Santé in Lille, France, talked about “Levels of competence in mpMRI reporting” and what urologists should expect (in terms of such competence) from the radiologists who conduct and “read” such MRIs and report their findings to the treating urologist (or radiologic oncologist).
What is clear from the last two of these lectures is that uptake of multiparametric MRI scanning as a key part of the work-up of prostate cancer patients is far more advanced in Europe than it is here in the USA. Cost is certainly a key factor here, because the cost of an mpMRI scan here in America is far higher than it is in most of the rest of the developed world.